# Heart Failure

Brittany Saldivar

---

## Background

ACC/AHA Stages of HF

- Stage A: At risk but without structural heart disease or symptoms
- Stage B: + structural HD, - symptoms
- Stage C: + structural HD, + prior or current symptoms
- Stage D: refractory HF requiring specialized intervention

NY Heart Association (NYHA) Functional Classes of HF

- Class I: Normal physical activity is not limited
- Class II: Comfortable at rest; normal physical activity results in
    HF symptoms
- Class III: Comfortable at rest; less than normal activity leads to
    HF symptoms
- Class IV: Inability to perform any physical activity without
    symptoms

## Etiologies

- HFrEF (Clinical diagnosis + LVEF \< 40%)
    - Ischemic: Obstructive CAD, previous/current myocardial
        infarction
    - Non-ischemic:
        - Load: HTN, valvulopathy
        - Arrhythmia: tachyarrhythmia, pacemaker induced
        - Myocardium
    - Toxins (EtOH, drugs, chemo, radiation),
    - Inflammatory (infections, AI),
    - Metabolic (thyroid, thiamine deficiency),
    - Infiltrative (amyloid, sarcoid, hemochromatosis)
    - Stress induced/takotsubo CM
        - Genetic
        - Idiopathic
- HFpEF: HTN, CAD, obesity, DM, infiltrative, hypertrophic
    cardiomyopathy

Causes of Heart Failure Exacerbations (FAILURES)

- Forgetting medications or taking drugs that can worsen HF (e.g. BB,
    CCB, NSAIDs, TZDs), chemo (anthracyclines, trastuzumab)
- Arrhythmia/Anemia: AF, VT, PVCs; Increased arrhythmia burden on
    device check?
- Ischemia/Infarction/Infection: myocarditis; Acute vascular
    dysfunction (e.g. endocarditis), especially mitral or aortic
    regurgitation.
- Lifestyle choices: Dietary indiscretions - high salt, EtOH,
    excessive fluid intake. Obesity.
- Upregulation (of CO): pregnancy and hyperthyroidism
- Renal failure: acute, progression of CKD, or insufficient dialysis
    (Increased preload)
- Embolus (pulmonary) or COPD (leads to increase right-sided
    afterload)
- Stenosis (worsening AS, RAS) leading to hypertensive crisis high
    left-sided afterload

## Presentation

- Volume overload: shortness of breath, dyspnea on exertion,
    Orthopnea, PND
- Nausea/poor po intake (hepatic and gut congestion)
- Confusion (decreased CO)
- Exam: Edema (legs, sacrum), rales, S3, S4, murmur (AS, MR), elevated
    JVD, + hepatojugular reflex, ascites

## Evaluation

- CBC, CMP, Magnesium, Lactate, TSH, iron studies
- Troponin, ECG
- BNP (Pro-BNP if on Entresto) – high negative predictive value for HF
    (false negative can occur in obese patients)
- CXR – differentiate other causes of dyspnea
- TTE
- Determine hemodynamic and volume profile
    - Cold vs warm
    - Dry vs wet

<table>
<colgroup>
<col style="width: 19%" />
<col style="width: 23%" />
<col style="width: 25%" />
<col style="width: 31%" />
</colgroup>
<thead>
<tr class="header">
<th>Cardiac Index</th>
<th></th>
<th>Euvolemia</th>
<th>Hypervolemia</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Low</td>
<td><p>Warm Extremities</p>
<p>Adequate UOP</p>
<p>Normal PPP</p></td>
<td><p>Warm and Dry</p>
<p>Forrester Class I</p>
<p>Tx: GDMT as tolerated</p></td>
<td><p>Warm and Wet</p>
<p>Forrester Class II</p>
<p>Tx: Diuresis, Vasodilators</p></td>
</tr>
<tr class="even">
<td>Normal</td>
<td><p>Cardiogenic Shock</p>
<p>Cool Extremities</p>
<p>Renal Failure</p>
<p>Narrow PP</p></td>
<td><p>Cold and Dry</p>
<p>Forrester Class III</p>
<p>Tx: Inotropes</p></td>
<td><p>Cold and Wet</p>
<p>Forrester Class IV</p>
<p>Tx: Diuresis +Tailored therapy (+/- vasodilators, inotropes)</p></td>
</tr>
</tbody>
</table>

## Management

- Telemetry, Daily STANDING weights, 2 L fluid restriction, 2g sodium
    diet, strict I/Os
- Diuresis: Place on 2.5 x home dose of IV diuretic, dose BID-TID
    (DOSE Trial)
- Goal is to be net negative (generally 1-2 L per day but patient
    dependent)
- Check BMP BID and Mg QD, keep K\>4 and Mg\>2
- Low threshold for substantial increase (double) in loop vs
    transition to drip if not diuresing adequately
- Can also augment with sequential nephron blockade (thiazides,
    acetazolamide)
- Continuation/optimization of GDMT (below)

---

# Guideline-Directed Medical Therapy for HFrEF

Brittany Saldivar

---

## General Principles

- Starting patients on low dose of multiple agents preferred to max
    dose of single agent
- D/C summary should have discharge weight, diuretic regimen, and
    renal function
- Daily weights at home with rescue diuretic plan (pm dose for 3 lbs
    in 1 day, 5 lbs in 3 days

<table>
<colgroup>
<col style="width: 22%" />
<col style="width: 26%" />
<col style="width: 26%" />
<col style="width: 25%" />
</colgroup>
<thead>
<tr class="header">
<th>Drug</th>
<th>Indication</th>
<th>Mechanism/ Benefits</th>
<th>Precautions</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td colspan="4">Beta Blockers</td>
</tr>
<tr class="even">
<td><p>Carvedilol</p>
<p>Metoprolol succinate</p>
<p>Bisoprolol</p></td>
<td><p>HFrEF &lt;40 %</p>
<p>Stage C HF (NYHA class I – IV)</p></td>
<td>Reduces catecholamine stimulation. Decreased HR, myocardial energy
demand, less adverse remodeling.</td>
<td><p>Avoid if pt is decompensated (cold); “start low and go slow”</p>
<p>Can continue during exacerbation if patient compensated</p></td>
</tr>
<tr class="odd">
<td colspan="4">ARNIs</td>
</tr>
<tr class="even">
<td>Sacubitril/ valsartan</td>
<td><p>HFrEF &lt; 40%</p>
<p>NYHA class II – IV</p>
<p>Used in place of ACE/ARB</p></td>
<td>Prevents vasoactive natriuretic peptide degradation involved in
pathogenesis of HF (+ action of ARB)</td>
<td><p>Need a 36 hr wash-out period if transitioning from ACEi to
ARNI</p>
<p>Hypotension</p>
<p>Risk of angioedema</p></td>
</tr>
<tr class="odd">
<td colspan="4">ACEIs</td>
</tr>
<tr class="even">
<td><p>Lisinopril</p>
<p>Enalapril</p>
<p>Captopril</p>
<p>Ramipril</p></td>
<td><p>HFrEF &lt;40 %</p>
<p>Stage C HF (NYHA class I – IV)</p></td>
<td>Blocks harmful effects of RAAS activation and attenuates adverse
cardiac and vascular remodeling</td>
<td><p>Risk of angioedema</p>
<p>Monitor renal function and K</p></td>
</tr>
<tr class="odd">
<td colspan="4">ARBs</td>
</tr>
<tr class="even">
<td><p>Losartan</p>
<p>Valsartan</p>
<p>Candesartan</p></td>
<td><p>HFrEF &lt;40 %</p>
<p>Stage C HF (NYHA class I – IV)</p></td>
<td>See ACEIs</td>
<td><p>See ACEIs</p>
<p>Preference for ARB &gt; ACEi if plans to start ARNI</p></td>
</tr>
<tr class="odd">
<td colspan="4">MRAs</td>
</tr>
<tr class="even">
<td><p>Eplerenone</p>
<p>Spironolactone</p></td>
<td><p>NYHA class II-IV and</p>
<p>GFR &gt;30</p></td>
<td>Diuretic and blood pressure lowering effects and blocks deleterious
effects of aldosterone on the heart (including hypertrophy and
fibrosis)</td>
<td>Hyperkalemia – avoid if CrCl &lt;30 or K &gt;5</td>
</tr>
<tr class="odd">
<td colspan="4">SGLT2i</td>
</tr>
<tr class="even">
<td><p>Dapagliflozin</p>
<p>Empagliflozin</p></td>
<td><p>HFrEF &lt;40% with and without DM</p>
<p>NYHA class II-IV</p>
<p>In conjunction with background GDMT</p></td>
<td>Osmotic diuresis and natriuresis, improve myocardial metabolism,
inhibit sodium-hydrogen exchange in myocardium, reduce cardiac
fibrosis</td>
<td><p>UTI/ GU infections</p>
<p>Risk of ketoacidosis (both DKA and euglycemic)</p></td>
</tr>
<tr class="odd">
<td colspan="4">Vasodilators</td>
</tr>
<tr class="even">
<td><p>Hydralazine</p>
<p>Isosorbide Dinitrate</p></td>
<td><p>Persistently symptomatic black patients despite ARNI/ BB/ MRA/
SGLT2i</p>
<p>NYHA class III-IV</p></td>
<td><p>Reduces cardiac afterload and preload and may also enhance nitric
oxide bioavailability</p>
<p>Reduction in mortality for African American patients</p></td>
<td>Hypotension</td>
</tr>
<tr class="odd">
<td colspan="4">Ivabradine</td>
</tr>
<tr class="even">
<td>Ivabradine</td>
<td><p>HFrEF &lt;35%, on maximally tolerated BB, sinus rhythm with HR
&gt; 70</p>
<p>NYHA class II or III</p></td>
<td><p>If current inhibitor involved in SA node activity</p>
<p>Decr HR associated with improved outcomes</p></td>
<td><p>Need sinus rhythm</p>
<p>Caution in sinus node disease and conduction defects</p></td>
</tr>
<tr class="odd">
<td colspan="4">Iron Repletion (IV)</td>
</tr>
<tr class="even">
<td><p>Iron sucrose</p>
<p>Ferric carboxymaltose</p>
<p>Iron dextran</p></td>
<td>Ferritin &lt;100 µg/L or ferritin 100-299 µg/L AND transferrin
saturation &lt;20%</td>
<td><p>Decreases HF hospitalizations</p>
<p>Improves exercise function and QOL</p></td>
<td>Risk of anaphylaxis higher in iron dextran</td>
</tr>
</tbody>
</table>

## Device therapies (after optimization of medical GDMT)

- Cardiac resynchronization therapy (CRT)
    - Class I indication: NYHA class II to IV, LVEF ≤35% with QRS ≥150 ms
    and left bundle branch block (LBBB)
    - Class II (consider) If EF \< 35% and:
        - QRSd \> 150, without LBBB
        - AF that requires ventricular pacing and AVN ablation
        - Undergoing placement of device with anticipation of \>40%
        ventricular pacing
- ICD
    - Class I indication: NYHA class II – VI with LVEF \<35% (must have
    \>1yr expected survival and 40+ days from MI)
- Mitra Clip
    - Criteria: moderate to severe mitral regurgitation (3-4+), on
    maximally tolerated GDMT, an ejection fraction \>20%, and a left
    ventricle end-systolic dimension of less than 7 cm
